Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Healthcare Biotechnology
Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Trillium Therapeutics Inc.
Bullboard Posts
User Avatar Image
(0)
•••
Comment by Croupier2on May 04, 2014 4:07pm
271 Views
Post# 22522807

RE:RE:They put a number on it

RE:RE:They put a number on itSince the IBB reversal, everything in preclinical is now trading lower than 50 % than 52 high. (some at 50 % of their last financing.)

besides the news, (licensing of none onco / stem cell asset) milestones to clinical, we could be surprise by partnership or simply CD47 feild progress (succes or failure of limited competiton)

btw, anyone spotted the CD47 Phase 1 trial in Ukraine (no joke)... that came out of the left feild.

Will have some news about Stanford, I kno someone will ask Weissman at New Orlean conference

Also, I am now 99% sure the Baker Bros led the last financing :)
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities